New Horizons GIST 2023

NEW_HORIZONS_GIST_2023_Dubli_Ireland_Briefkopf_L1

NEW HORIZONS GIST is the most important global annual conference for GIST patient advocates. At NEW HORIZONS GIST, patients from the global GIST patient community come together, can interact with top GIST experts, have access to state‐of‐the‐art medical and scientific information and can exchange best practice in patient advocacy among each other. The conference is a balanced symbiosis of medical content, advocacy topics and capacity building sessions. After more than 2 years living under the restrictions of the pandemic, we are happy to annouce that NEW HORIZONS GIST will be held as a hybrid meeting in 2023.

On behalf of the “NEW HORIZONS GIST Steering Committee”, we are very pleased to announce the 2023 NEW HORIZONS GIST Conference May 13 & 14 in Dublin, Ireland and online via Zoom - for the first time in conjunction with the SPAGN Annual Conference.

We are looking forward to seeing you again - online or onsite!

 

The location:
Onsite: Crowne Plaza Dublin - Blanchardstown, Blanchardstown Town Centre, Dublin 15, Ireland
Online via Zoom, more information will be shared with registered participants in due course.

Please register here.

Please find below the preliminary program.

 

SATURDAY May 13, 2023 - HYBRID
14:00 (15) Opening & Welcome
NH GIST Steering Committee
14:15 – 16:00
(105)
Session Chair/s: Martin Wettstein & Piga Fernandez

How to treat GIST (Gastrointestinal Stromal Tumors) qualified today?
The previous therapy algorithms: overview and changes/innovations

  • The localized disease
  • The metastatic disease
  • The progressive disease
16:00 – 16:30   C O F F E E   B R E A K
16:30 – 18:15
(105)
Session Chair/s: Sara Rothschild & Ginger Sawyer

Scientific evidence and expert evidence (= practical clinical experience)
with the two latest approved GIST therapies:

  • Fourth line: Ripretinib (Qinlock®)
  • For GIST Exon D842V: Avapritinib (Ayvakit® / Ayvakyt®)
18:15 – 19:30   B R E A K   B E F O R E   D I N N E R
19:30               Onsite: Conference Dinner

 

SUNDAY May 14, 2023 - HYBRID
10:00 – 12:30
(150)

incl. break (15)

Working Group
Session Chair/s: David Josephy & Markus WartenbergGIST-Patients urgently need innovations and improvements for survival and better quality of life. What are the top research questions/priorities from the patient-perspective? Let's identify and prioritize unanswered questions or evidence uncertainties in GIST!

  • Phase 1: Before the conference, we will collect research questions and priorities from the global GIST patient advocacy community.
  • Phase 2: During the conference we will discuss a list of the most frequently mentioned topics with each other and with leading GIST-Experts.

Our goal: A 10-point list with the main research questions/
priorities from the perspective of GIST patients.

12:30 – 13:30   L U N C H 
13:30 – 15:15
(105)
Session Chair/s: Jayne Bressington & Gerard van Oortmerssen

Right from the start, GISTs were one of the first cancer diseases for “precision oncology”. That means: The right therapy for specific mutations/target structures. One challenge today are rare and very rare
GIST subtypes (e.g. rare exon mutations and non-KIT/-PDGFRA GIST).

  • General overview of rare and very rare GISTs -
    biology, genetics and profiles of the individual subtypes
  • How to treat rare GIST-subtypes – scientific & expert evidence
  • Patients and experts are working closely together in rare GIST subtypes: The UK-experience
15:15 – 15:45   C O F F E E   B R E A K
15:45 – 17:30
(105)
Session Chair/s: David Josephy & Markus Wartenberg

Part A: Where does the GIST research journey currently take us?

What's happening…

  • in basic research…
  • in clinical research / in clinical studies

 

Part B: Morning results of this conference: Findings from a survey among the global GIST patient advocacy community and from a workshop today with leading GIST-Experts: A 10-point list with the main research questions/priorities from the perspective of GIST patients…

17:30              Wrap Up & Farewell - OFFICIAL END OF THE CONFERENCE